L-Ascorbic Acid Co-Administration to Block Statin-Induced Vascular Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Statins, despite their benefits in reducing cardiovascular disease risk, induce vascular calcification, a significant risk factor for heart disease, and existing treatments do not effectively mitigate this side effect.
Innovation Solution
Concomitant administration of L-ascorbic acid or ascorbate with statins, either alone or in a pharmaceutical composition, to prevent or treat vascular calcification, potentially combined with coenzyme Q10 and other micronutrients, to counteract the calcification process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are administered to reduce LDL cholesterol and prevent cardiovascular disease, then cardiovascular protection is improved, but vascular calcification increases
Solution Approach 1:
Vitamin C acts as an intermediary substance that mediates between statin therapy and vascular calcification. The patent shows that vitamin C co-administration blocks the calcification-inducing effects of statins on vascular smooth muscle cells, allowing statins to maintain their cardiovascular protective effects while preventing the harmful calcification side effect through the intermediary action of vitamin C
Solution Approach 2:
The patent converts the harmful effect of statin-induced calcification into a beneficial outcome by using vitamin C to transform the calcification process. Instead of allowing calcification to proceed as a harmful side effect, vitamin C redirects the process to produce stable plaque formations that are less prone to rupture, thereby converting a harmful effect into a potentially beneficial structural stabilization
2Reliability
If statins are used for primary and secondary prevention of cardiovascular disease, then cardiovascular risk is reduced, but vascular calcification develops
Solution Approach 1:
Vitamin C is administered concurrently with statins to preemptively counteract the calcification-inducing effects before they can manifest as harmful vascular calcification. The patent demonstrates that vitamin C pre-treatment or co-treatment blocks the activation of calcification pathways in vascular smooth muscle cells that would otherwise be triggered by statin therapy
3Stability of the object's composition
If statin therapy is administered to lower LDL cholesterol, then atherosclerosis progression is slowed, but arterial calcification increases
Solution Approach 1:
Vitamin C serves as a mediating substance that allows statins to maintain their beneficial effect of slowing atherosclerosis progression while simultaneously blocking the harmful calcification pathway. The patent shows that vitamin C interferes with the statin-induced differentiation of vascular smooth muscle cells into osteoblastic cells, thereby preventing arterial calcification without compromising the anti-atherosclerotic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
L-ascorbic acid effectively inhibits vascular calcification by reducing alkaline phosphatase activity and calcium accumulation in smooth muscle cells, thereby mitigating the calcification process induced by statins, thus addressing the conflicting evidence on statin effects on cardiovascular health.
Implementation Method 1
L-ascorbic acid effectively inhibits vascular calcification by reducing alkaline phosphatase activity and calcium accumulation in smooth muscle cells
Implementation Method 2
L-ascorbic acid effectively inhibits vascular calcification by reducing alkaline phosphatase activity and calcium accumulation in smooth muscle cells
Data Source
AI summary
A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.